Huang Jian-jun, Zeng Qiang, Yu Jia-lu
Department of Respiratory Diseases, Guangzhou Children's Hospital, Guangzhou 510120, China.
Di Yi Jun Yi Da Xue Xue Bao. 2005 Sep;25(9):1199-200.
To evaluate the therapeutic effects and safety of cefepime (Maxipime) and sulbactam/cefoperazone (sulperazone) on moderate and severe respiratory infection in children.
Totally 100 children hospitalized for pneumonia were randomized equally into 2 groups, namely group A with maxipime treatment at the dose of 50 mg/kg given intravenously twice daily, and group B with sulperazone treatment at 50-100 mg/kg given intravenously twice a day. The therapeutic effects and safety of both medications were observed.
In maxipime group, 44 of the 50 cases were cured with complete elimination of the symptoms and signs, and obvious therapeutic effect was achieved in 5 cases with significant improvement or resolution of the majority of symptoms and signs. One case failed to respond favorably to the treatment, with the overall efficacy rate of 98% without incidence of adverse effects. In sulperazone group, 40 of the 50 cases were cured, 6 showed significant improvement, and 4 failed to respond to the treatment, with the rate of 92%. One patient complained of rashes during sulperazone treatment, which disappeared the next day without sulperazone withdrawal. Significant difference was not noted between the groups (chi(2)=2.43, P>0.05).
Both maxipime and sulperazon are effective and safe for application in children with moderate and severe respiratory infections.
评估头孢吡肟（马斯平）与舒巴坦/头孢哌酮（舒普深）治疗儿童中重度呼吸道感染的疗效及安全性。
将100例因肺炎住院的儿童随机均分为2组，即A组采用马斯平治疗，剂量为50mg/kg，静脉滴注，每日2次；B组采用舒普深治疗，剂量为50 - 100mg/kg，静脉滴注，每日2次。观察两种药物的疗效及安全性。
马斯平组50例中，44例症状体征完全消失治愈，5例症状体征大部分明显改善或消失，显效，1例治疗无效，总有效率98%，无不良反应发生。舒普深组50例中，40例治愈，6例显效，4例无效，有效率92%。1例在舒普深治疗期间出现皮疹，次日自行消退，未停药。两组间差异无统计学意义（χ² = 2.43，P > 0.05）。
马斯平和舒普深治疗儿童中重度呼吸道感染均安全有效。
